{"id":"normal-injection-of-enoxaparine","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Injection site hematoma"},{"rate":"1-3%","effect":"Elevated transaminases"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin formation, thereby reducing clot formation. It is administered by subcutaneous injection and has predictable pharmacokinetics compared to unfractionated heparin.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:43.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of venous thromboembolism in surgical patients"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"},{"name":"Prophylaxis in medically ill patients at risk of thromboembolism"},{"name":"Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)"}]},"trialDetails":[{"nctId":"NCT05129800","phase":"","title":"Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2011-01-01","conditions":"Androgenetic Alopecia, Hair Loss, Alopecia","enrollment":72},{"nctId":"NCT06662240","phase":"NA","title":"Effect of Vibration Anesthesia on Pain, Ecchymosis and Comfort Level in Subcutaneous Heparin Injection","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2024-03-15","conditions":"Pain, Ecchymosis, Comfort","enrollment":142},{"nctId":"NCT04918524","phase":"","title":"The Clinical Features and Pregnancy Outcomes of CTD Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-09-11","conditions":"Connective Tissue Diseases, Pregnancy Related","enrollment":126},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT02325479","phase":"PHASE1","title":"Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)","status":"COMPLETED","sponsor":"The Egyptian IVF-ET Center","startDate":"2015-01","conditions":"Infertility","enrollment":120},{"nctId":"NCT02379663","phase":"PHASE4","title":"Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures","enrollment":639},{"nctId":"NCT00412802","phase":"PHASE4","title":"Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"French Cardiology Society","startDate":"2006-12","conditions":"Acute Coronary Syndrome, Renal Failure","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"normal injection of Enoxaparine","genericName":"normal injection of Enoxaparine","companyName":"French Cardiology Society","companyId":"french-cardiology-society","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}